{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T02:29:32Z","timestamp":1790908172077,"version":"4.1.0"},"reference-count":7,"publisher":"Massachusetts Medical Society","issue":"20","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["N Engl J Med"],"published-print":{"date-parts":[[1988,5,19]]},"DOI":"10.1056\/nejm198805193182002","type":"journal-article","created":{"date-parts":[[2010,7,28]],"date-time":"2010-07-28T17:45:00Z","timestamp":1280339100000},"page":"1292-1294","source":"Crossref","is-referenced-by-count":146,"title":["Anagrelide: A New Drug for Treating Thrombocytosis"],"prefix":"10.1056","volume":"318","author":[{"given":"Murray N.","family":"Silverstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M.","family":"Petitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Lawrence A.","family":"Solberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Stuart","family":"Fleming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald C.","family":"Knight","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee P.","family":"Schacter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"150","reference":[{"key":"r001","unstructured":"Fleming JS, Buyniski JP. Anagrelide. In: Scriabine A, ed. New drugs annual: cardiovascular drugs. Vol. 1. New York: Raven Press, 1983:277."},{"key":"r002","unstructured":"Silverstein MN. Diagnosis and treatment of polycythemia vera, agnogenic myeloid metaplasia, and primary thrombocythemia. In: Wiernik PH, Canellos GP, Kyle RA, Schiffer CA, eds. Neoplastic diseases of the blood. New York: Churchill-Livingstone, 1984:135."},{"key":"r003","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/jcp.1041240112","volume":"124","author":"Solberg","year":"1985","journal-title":"J Cell Physiol"},{"key":"r004","unstructured":"Silverstein MN. Essential thrombocythemia. In: Williams WJ, ed. Hematology. New York: McGraw-Hill, 1983:218."},{"key":"r005","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1056\/NEJM198102193040801","volume":"304","author":"Berk","year":"1981","journal-title":"N Engl J Med"},{"key":"r006","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/ajh.2830170402","volume":"17","author":"Donovan","year":"1984","journal-title":"Am J Hematol"},{"key":"r007","unstructured":"Anagrelide for platelet reduction in patients with polycythemia vera and essential thrombocythemia (protocol no. 020W1). Wallingford, Conn.: Bristol-Myers Pharmaceutical Research and Development Division, 1986."}],"container-title":["New England Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJM198805193182002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,19]],"date-time":"2017-06-19T07:47:50Z","timestamp":1497858470000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.nejm.org\/doi\/abs\/10.1056\/NEJM198805193182002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1988,5,19]]},"references-count":7,"journal-issue":{"issue":"20","published-print":{"date-parts":[[1988,5,19]]}},"alternative-id":["10.1056\/NEJM198805193182002"],"URL":"https:\/\/doi.org\/10.1056\/nejm198805193182002","relation":{},"ISSN":["0028-4793","1533-4406"],"issn-type":[{"value":"0028-4793","type":"print"},{"value":"1533-4406","type":"electronic"}],"subject":[],"published":{"date-parts":[[1988,5,19]]}}}